Understand the source comparison
How to Improve Gut Health with Peptides: Mechanism Comparison
BPC-157 VEGF upregulation, tight junction repair, mucosal angiogenesis Gastric mucosa, small intestine, colon Oral (empty stomach) or subcutaneous 250–500 mcg SC or 500–1000 mcg oral Best-documented for barrier repair and ulcer healing. Stable in gastric acid,
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF upregulation, tight junction repair, mucosal angiogenesis
- Gastric mucosa, small intestine, colon
- Oral (empty stomach) or subcutaneous
- 250–500 mcg SC or 500–1000 mcg oral
- Best-documented for barrier repair and ulcer healing. Stable in gastric acid, which oral peptides rarely achieve
- KPV
- NF-κB inhibition, cytokine suppression
- Intestinal epithelium, lamina propria
- Oral (enteric-coated), rectal enema, or subcutaneous
- 500–2000 mcg rectal or 200–500 mcg SC
- Most effective for inflammatory conditions (IBD, IBS). Rectal administration outperforms oral for distal colitis
- Thymosin Beta-4
- Actin regulation, immune modulation, tight junction upregulation
- Intestinal barrier, immune cells
- Subcutaneous
- 2–5 mg SC twice weekly
- Rebuilds barrier integrity at the protein level. Particularly useful post-antibiotic or after NSAIDs damage tight junctions
- LL-37
- Antimicrobial activity, barrier protection, immune signalling
- Mucosal surface, epithelial cells
- Topical (enema) or subcutaneous
- 1–2 mg SC or rectal
- Dual antimicrobial and anti-inflammatory. Addresses dysbiosis-driven inflammation without disrupting beneficial flora
- MK 677 (Ghrelin mimetic)
- Growth hormone secretagogue, motilin release, gastric emptying acceleration
- Stomach, small intestine
- Oral
- 10–25 mg oral before bed
- Improves motility disorders (gastroparesis, constipation). But causes transient hunger and mild insulin resistance in some users